Prohemostatic therapy: The rise and fall of aprotinin

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 1, 2010, Pages 103-112

  Vande Vusse, Lisa K ^a   Zacharski, Leo R ^a   Dumas, Maura G ^a   McKernan, Laurel J ^a   Cornell, Cornelius J ^a   Kinsler, Erron A ^b   Whiteside, James L ^b  

^a Department of Medicine   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Aprotinin; Blood transfusion; Iron toxicity; Prohemostatic therapy

Indexed keywords

AMINOCAPROIC ACID; APROTININ; FRESH FROZEN PLASMA; PLACEBO; TRANEXAMIC ACID; WARFARIN;

ADENOIDECTOMY; ANAMNESIS; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FAMILY HISTORY; HEMOSTASIS; HUMAN; LIVER SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TONSILLECTOMY;

ADOLESCENT; AGED; APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; FEMALE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; RISK FACTORS;

EID: 77951064217     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1248729     Document Type: Review

References (107)

1. Mannucci P M., Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007 356 (22) 2301-2311
2. Levy J H. Massive transfusion coagulopathy. Semin Hematol 2006 43 (suppl 1) S59-S63
3. Mahdy A M., Webster N R. Perioperative systemic haemostatic agents. Br J Anaesth 2004 93 (6) 842-858
4. Levi M, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002 76 (suppl 2) 139-144
5. Segal H, Hunt B J. Aprotinin: pharmacological reduction of perioperative bleeding. Lancet 2000 355 1289-1290
6. Jurlander B, Thim L, Klausen N K. et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001 27 (4) 373-384
7. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006 32 (suppl 1) 77-85
8. Sodha N, Boodhwani M, Bianchi C, Ramlawi B, Sellke F. Aprotinin in cardiac surgery. Expert Rev Cardiovasc Ther 2006 4 (2) 151-160
9. Ickx B, Van der Linden P, Melot C et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Transfusion 2006 46 (4) 595-605
10. Shiga T, Wajima Z, Inoue T, Sakamoto A. Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials. Anesth Analg 2005 101 (6) 1602-1607
11. Stewart A, Newman L, Sneddon K, Harris M. Aprotinin reduces blood loss and the need for transfusion in orthognathic surgery. Br J Oral Maxillofac Surg 2001 39 (5) 365-370
12. Vaporciyan A A., Putnam J B. Jr, Smythe W R. The potential role of aprotinin in perioperative management of malignant tumors. J Am Coll Surg 2004 198 (2) 266-278
13. Lamarra M, Azzu A A., Kulatilake E N. Cardiopulmonary bypass in the early puerperium: possible new role for aprotinin. Ann Thorac Surg 1992 54 (2) 361-363
14. Sher G. Trasylol in the management of abruptio placentae with consumption coagulopathy and uterine inertia. J Reprod Med 1980 25 (3) 113-118
15. Stroup J, Haraway D, Beal J M. Aprotinin in the management of coagulopathy associated with amniotic fluid embolus. Pharmacotherapy 2006 26 (5) 689-693 (Pubitemid 43673051)
16. Joly L M., Sermet A, Turak B, Samama C M. Hemorragie massive aprs laminectomie dorsale dcompressive [Massive haemorrhage after dorsal decompressive laminectomy] [in French]. Ann Fr Anesth Reanim 2005 24 (10) 1278-1281
17. Palmer J D., Francis J L., Pickard J D., Ianottie F. The efficacy and safety of aprotinin during intracranial surgery. J Neurosurg 2003 98 (6) 1208-1216 (Pubitemid 36617923)
18. van Oeveren W, Harder M P., Roozendaal K J., Eijsman L, Wildevuur C R. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990 99 (5) 788-796
19. Boeken U, Litmathe J, Kurt M, Feindt P, Gams E. CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tirofiban (Aggrastat): modification of perioperative management? Int J Cardiol 2008 127 (2) 257-259 (Pubitemid 351787773)
20. Ouattara A, Bouzguenda H, Le Manach Y, Lger P, Mercadier A, Leprince P. Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin. Eur Heart J 2007 28 (8) 1025-1032 (Pubitemid 47343913)
21. Roath O S., Majer R V., Smith A G. The use of aprotinin in thrombocytopenic patients: a preliminary evaluation. Blood Coagul Fibrinolysis 1990 1 (2) 235-237
22. Bidstrup B P., Royston D, Taylor K M., Sapsford R N. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery. Lancet 1988 1 (8581) 366-367 (Pubitemid 18057789)
23. Mayer S A., Rincon F. Ultra-early hemostatic therapy for acute intracerebral hemorrhage. Semin Hematol 2006 43 (1, suppl 1) S70-S76 (Pubitemid 43150503)
24. Vanek T, Jarez M, Fajt T et al. Fibrinolytic inhibitors in off pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur J Cardiothorac Surg 2005 28 (4) 563-568
25. Beierlein W, Scheule A, Dietrich W, Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 2005 79 (2) 741-748 (Pubitemid 40186610)
26. Mahdy A M., Webster N R. Perioperative systemic haemostatic agents. Br J Anaesth 2004 93 (6) 842-858
27. Bayer Health Care Pharmaceuticals. Product information on Trasylol including warnings. Available at: http://www.trasylol.com/ Accessed December 1, 2009
28. Weber R S., Jabbour N, Martin R C. Anemia and transfusions in patients undergoing surgery for cancer. Ann Surg Oncol 2008 15 (1) 34-45
29. Hjalgrim H, Edren G, Rostgaard K et al. Cancer incidence in blood transfusion recipients. J Natl Cancer Inst 2007 99 (24) 1864-1874 (Pubitemid 351767194)
30. Murphy G J., Reeves B C., Rogers C A., Rizvi S I., Culliford L, Angelini G D. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007 116 (22) 2544-2552 (Pubitemid 350179219)
31. Jani S M., Smith D E., Share D et al. Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. Clin Cardiol 2007 30 (10, suppl 2) 1149-1156
32. Rao S V., Jollis J G., Harrington R A. et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004 292 (13) 1555-1562
33. Bilgin Y M., van de Watering L M., Eijsman L, Versteegh M I., van Oers M H., Brand A. Is increased mortality associated with post-operative infections after leukocytes containing red blood cell transfusions in cardiac surgery? An extended analysis. Transfus Med 2007 17 (4) 304-311
34. Abu-Rustum N R., Richard S, Wilton A et al. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol Oncol 2005 99 (2) 320-326
35. Gangireddy C, Rectenwald J R., Upchurch G R. et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007 45 (2) 335-341 discussion 341-342
36. Nilsson K R., Berenholtz S M., Garrett-Mayer E, Dorman T, Klag M J., Pronovost P J. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg 2007 142 (2) 126-132
37. Yeh J J., Gonen M, Tomlinson J S., Idrees K, Brennan M F., Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg 2007 94 (4) 466-472
38. Khorana A A., Francis C W., Blumberg N, Culakova E, Refaai M A., Lyman G H. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008 168 (21) 2377-2381
39. Landis R C., Asimakopoulos G, Poullis M, Haskard D O., Taylor K M. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001 72 (6) 2169-2175
40. Poston R S., White C, Gu J et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006 81 (1) 104-110
41. Chabbat J, Porte P, Tellier M, Steinbuch M. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res 1993 71 (3) 205-215
42. Spannagl M, Dietrich W, Beck A, Schramm W. High dose aprotinin reduces prothrombin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial revascularization. Thromb Haemost 1994 72 (1) 159-160
43. Desai P H., Kurian D, Thirumavalavan N et al. A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery. Anesth Analg 2009 109 (5) 1387-1394
44. Bittner H, Richter M, Kuntze T et al. Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation. Eur J Cardiothorac Surg 2006 29 (2) 210-215
45. Harmon D, Ghori K, Eustace N, OCallaghan S, ODonnell A, Shorten G. Aprotinin the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth 2004 51 (10) 1002-1009 (Pubitemid 40104116)
46. Williams A, Gettinger A. Transfusion therapy in the intensive care unit. Curr Opin Anaesthesiol 2006 19 (2) 127-131
47. Fortenberry J D., Meier A H., Pettignano R, Heard M, Chambliss C R., Wulkan M. Extracorporeal life support for posttraumatic acute respiratory distress syndrome at a childrens medical center. J Pediatr Surg 2003 38 (8) 1221-1226 (Pubitemid 37048046)
48. Latner A, Longstaff E, Turner G A. Anti-tumor activity of aprotinin. Br J Cancer 1974 30 (1) 60-67
49. Zacharski L R. Malignancy as a solid phase coagulopathy: implications for the etiology, pathogenesis and treatment of cancer. Semin Thromb Hemost 2003 29 (3) 239-246
50. Dunbar S D., Ornstein D L., Zacharski L R. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Expert Opin Investig Drugs 2000 9 (9) 2085-2092
51. Lentschener C, Li H, Franco D et al. Intraoperatively administered aprotinin increases one year survival after elective liver resection for colorectal metastasis. Anesthesiology 1998 89 (3A) A1186
52. Lentschener C, Li H, Franco D et al. Intraoperatively-administered aprotinin and survival after elective liver resection for colorectal cancer metastasis. A preliminary study. Fibrinolysis Proteolysis 1999 13 (1) 39-45 (Pubitemid 29210839)
53. Norman P H., Thall P F., Purugganan R V. et al. A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer 2009 115 (4) 833-841
54. Tucker T A., Dean C, Komissarov A et al. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells. Am J Respir Cell Mol Biol 2009 July 27 (Epub ahead of print)
55. Royston D, Bidstrup B P., Taylor K M., Sapsford R N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987 2 (8571) 1289-1291 (Pubitemid 17156632)
56. Beighton P, Solomon L, Soskolne C L. Articular mobility in an African population. Ann Rheum Dis 1973 32 (5) 413-418
57. Kinsler E L., Vande Vusse L K., Malone M G., Zacharski L R., Whiteside J L. Pelvic organ prolapse associated with hypermobility syndrome and operative bleeding managed with aprotinin. J Pelvic Med Surg 2008 14 (1) 65-68
58. Dirkmann D, Hanke A A., Grlinger K, Peters J. Perioperative use of modified thromboelastography in factor XI deficiency: a helpful method to assess drug effects. Acta Anaesthesiol Scand 2007 51 (5) 640-643 (Pubitemid 46570044)
59. Eber W N. Massive blood transfusion in the elective surgical setting. Transfus Apheresis Sci 2002 27 (1) 83-92 (Pubitemid 34663872)
60. Palanzo D A., Sadr F S. Coronary artery bypass grafting in a patient with haemophilia B. Perfusion 1995 10 (4) 265-270
61. Greaves M, Watson H G. Approach to the diagnosis and management of mild bleeding disorders. J Thromb Haemost 2007 5 (suppl 1) 167-174 (Pubitemid 46958830)
62. Henry D A., Carless P A., Moxey A J. et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007 (4) CD001886
63. Karkouti K, Beattie W S. Propensity score case-control comparison of aprotinin and tranexamic acid in high transfusion-risk cardiac surgery. Transfusion 2006 46 (3) 327-338 (Pubitemid 43334084)
64. Mangano D T., Tudor I C., Dietzel A C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 (4) 353-365 (Pubitemid 43145060)
65. Mangano D T., Miao Y, Vuylsteke A et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007 297 (5) 471-479 (Pubitemid 46220802)
66. U.S. Food and Drug Administration. Aprotinin injection (marketed as Trasylol) information [updated May 14, 2008; cited May 29]. Available at: http://www.fda.gov/cder/drug/infopage/aprotinin/default.htm See also: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ucm142720.htm Accessed November 27, 2009
67. Trasylol Public Health Advisory Update. Available at: http://factsandcomparisons.com/News/ArticlePage.aspx?id=7387 Accessed January 25, 2010
68. Sedrakyan A, Treasure T, Elefteriades J A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004 128 (3) 442-448 (Pubitemid 39194703)
69. Brown J R., Birkmeyer N J., OConnor G T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007 115 (22) 2801-2813
70. Furnary A P., Wu Y, Hiratzka L F., Grunkemeier G L., Page U S. III. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007 116 (11, suppl) 1127-1133
71. Rogers M A., Blumberg N, Saint S K., Kim C, Nallamothu B K., Langa K M. Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery. Am Heart J 2006 152 (6) 1028-1034 (Pubitemid 44856710)
72. Koch C G., Li L, Duncan A I. et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006 34 (6) 1608-1616 (Pubitemid 43810038)
73. Madjdpour C, Heindl V, Spahn D R. Risks, benefits, alternatives and indications of allogeneic blood transfusions. Minerva Anestesiol 2006 72 (5) 283-298 (Pubitemid 43773125)
74. Meyers D G., Jensen K C., Menitove J E. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 2002 42 (9) 1135-1139
75. Zacharski L R., Chow B K., Howes P S. et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease. JAMA 2007 297 (6) 603-610
76. Gupta A, Sharma S, Kaur I, Chopra K. Renoprotective effects of sesamol in ferric nitrilotriacetate-induced oxidative renal injury in rats. Basic Clin Pharmacol Toxicol 2009 104 (4) 316-321
77. Zhong Y, Onuki J, Yamasaki T, Ogawa O, Akatsuka S, Toyokuni S. Genome-wide analysis identifies a tumor suppressor role for aminoacylase 1 in iron-induced rat renal cell carcinoma. Carcinogenesis 2009 30 (1) 158-164
78. Levy J H. Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes. J Thromb Haemost 2006 4 (9) 1875-1878 (Pubitemid 44226760)
79. Karkouti K, Beattie W S. Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: no. J Thromb Haemost 2006 4 (9) 1879-1881 (Pubitemid 44226761)
80. Ferraris V A., Bridges C R., Anderson R P. Aprotinin in cardiac surgery. N Engl J Med 2006 354 (18) 1953-1957
81. Bridges C R. Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation 2007 115 (22) 2790-2792
82. Ferguson T B. Jr. Aprotininare there lessons learned? JAMA 2007 297 (5) 527-529
83. Levy J H. Aprotinin versus tranexamic acid: the controversy continues. Transfusion 2006 46 (3) 319-320
84. Ray W A. Learning from aprotininmandatory trials of comparative efficacy and safety needed. N Engl J Med 2008 358 (8) 840-842
85. Schneeweiss S, Seeger J D., Landon J, Walker A M. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008 358 (8) 771-783 (Pubitemid 351284455)
86. Shaw A D., Stafford-Smith M, White W D. et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008 358 (8) 784-793
87. Fergusson D A., Hebert P C., Mazer D et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008 358 (22) 2319-2331
88. Murkin J M. Lessons learned in antifibrinolytic therapy: the BART trial. Semin Cardiothorac Vasc Anesth 2009 13 (2) 127-131
89. Ray W A., Stein C M. The aprotinin storyis BART the final chapter? N Engl J Med 2008 358 (22) 2398-2400
90. Eser O, Kalkan E, Cosar M et al. The effect of aprotinin on brain ischemic-reperfusion injury after hemorrhagic shock in rats: an experimental study. J Trauma 2007 63 (2) 373-378
91. Hruby Z, Wendycz D, Kope W, Zieliski B, Paczek L, Soin J. Mechanism of antinephritic effect of proteinase inhibitors in experimental anti-GBM glomerulopathy. Res Exp Med (Berl) 2000 199 (5) 295-307
92. Dietrich W, Busley R, Boulesteix A L. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin. Anesthesiology 2008 108 (2) 189-198
93. Backer C L., Kelle A M., Stewart R D. et al. Aprotinin is safe in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2007 134 (6) 1421-1426
94. Stamou S C., Reames M K., Skipper E et al. Aprotinin in cardiac surgery patients: is the risk worth the benefit? Eur J Cardiothorac Surg 2009 36 (5) 869-875
95. Inamura Y, Miyamae M, Sugioka S et al. Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase C-delta and glycogen synthase kinase 3beta. Anesthesiology 2009 111 (5) 1036-1043
96. Jakobsen C J., Sndergaard F, Hjortdal V E., Johnsen S P. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study. Eur J Cardiothorac Surg 2009 36 (5) 863-868
97. Reeves B C., Murphy G J., Rogers C A., Culliford L, Rizvi S I., Angelini G D. Response to letter regarding article, Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery Circulation 2008 117 (25) e507
98. Ishibashi N, Iwata Y, Zurakowski D, Lidov H G., Jonas R A. Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass. Perfusion 2009 24 (2) 99-105
99. Nicolau-Raducu R, Subramaniam K, Marquez J, Wells C, Hilmi I, Sullivan E. Safety and efficacy of tranexamic acid compared with aprotinin in thoracic aortic surgery with deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 2010 24 (1) 73-79
100. Wang X, Zheng Z, Ao H et al. A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China. J Thorac Cardiovasc Surg 2009 138 (4) 897-903
101. Ramlawi B, Otu H, Russo M J., Novick R J., Bianchi C, Sellke F W. Aprotinin attenuates genomic expression variability following cardiac surgery. J Card Surg 2009 24 (6) 772-780
102. Choi H C., Lee K Y., Lee D H., Kang Y J. Heme oxygenase-1 induced by aprotinin inhibits vascular smooth muscle cell proliferation through cell cycle arrest in hypertensive rats. Korean J Physiol Pharmacol 2009 13 (4) 309-313
103. Zacharski L R., Chow B K., Howes P S. et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008 100 (14) 996-1002
104. Spinella P C., Perkins J G., McLaughlin D F. et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 2008 64 (2) 286-293
105. Holt R L., Martin T D., Hess P J., Beaver T M., Klodell C T. Jehovahs Witnesses requiring complex urgent cardiothoracic surgery. Ann Thorac Surg 2004 78 (2) 695-697
106. Aprotinin US Special Access Protocol. Available at: http:// clinicaltrials.gov/ct2/show/NCT00611845 Expanded access is currently available for this treatment. Verified by Bayer, September 2009. First received January 29, 2008; last updated September 28, 2009
107. Society of Cardiovascular Anesthesiologists. PRO: Aprotinin use is justified in all high-risk cardiac surgery. Available at: http://www.scahq.org/ sca3/newsletters/oct-pro.shtml Accessed December 1, 2009